October 8, 2008 — Preliminary data from a large, 4-year, company-sponsored study of about 6000 patients suggest that the inhaled, long-acting anticholinergic agent tiotropium bromide (Spiriva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback